EPR Properties vs Incyte Corporation — how do they compare? EPR Properties trades at $54.74 (market cap $4.17B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 5.5× EPR Properties's market cap, and EPR Properties pays a 6.84% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold EPR Properties for 46 Days and Incyte Corporation for 33 Days on average.
| EPR | INCY | |
|---|---|---|
Market Cap | $4.17B | $22.85B |
Volume | 992,716 | 1,927,029 |
Sector | Real Estate | Health |
52-Week High | $64.32 | $129.93 |
52-Week Low | $48.71 | $83.80 |
Typical Hold Time | 46 Days | 33 Days |
Enterprise Value | $7.68B | $18.35B |
Dividend Yield | 6.84% | — |
Signals from Pluang's Aura AI — not financial advice
EPR Properties trades at $54.41, up 0.61% today, with a bearish technical signal but oversold oscillators suggesting potential reversal. The REIT reported strong profitability with a 37.66% net income margin and a 6.5% dividend yield, though Q1 2026 earnings missed expectations. Recent news highlights its appeal for income investors, with monthly dividends and diversification into theme parks and fitness.
Outlook is mixed: analyst consensus is a Buy with a $65.50 target, but technicals and a projected 2026 net income decline pose risks. The stock offers value at a P/E of 17.44 and high yield, yet investors face headwinds from rising Treasury yields and competitive pressures in the net lease REIT sector.
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →